Shingles Vaccine Halves Serious Heart Events in Patients with Existing Cardiovascular Disease, New Research Reveals

New research presented at the American College of Cardiology’s Annual Scientific Session (ACC.26) has revealed a compelling link between shingles vaccination and significantly reduced cardiovascular risks in individuals already living with heart disease. The study, which analyzed data from over 246,000 adults, found that those with atherosclerotic heart disease who received a shingles vaccine experienced nearly half the rate of serious heart-related events within a year compared to their unvaccinated counterparts. This landmark finding adds substantial weight to the growing body of evidence suggesting that the benefits of the shingles vaccine extend far beyond preventing the painful rash of herpes zoster, potentially offering a vital layer of protection for the heart.

A Deeper Dive into the Cardioprotective Effects

The study’s findings are particularly striking given the vulnerability of the population examined. Researchers meticulously reviewed health data for 246,822 adults across the United States diagnosed with atherosclerotic heart disease (ASCVD), a condition characterized by plaque buildup in the arteries that can lead to heart attacks, strokes, and other severe cardiovascular complications. Within this high-risk group, vaccinated individuals showed a remarkable 46% lower likelihood of experiencing a major adverse cardiac event (MACE) and a substantial 66% reduction in all-cause mortality within the year following vaccination.

The specific reductions in cardiovascular events were equally impressive: the risk of heart attack dropped by 32%, stroke by 25%, and heart failure by 25% among vaccinated patients. Dr. Robert Nguyen, a resident physician at the University of California, Riverside, and the study’s lead author, underscored the magnitude of these results. "This vaccine has been found over and over again to have cardioprotective effects for reducing heart attack, stroke, and death," Dr. Nguyen stated. "Looking at the highest risk population, those with existing cardiovascular disease, these protective effects might be even greater than among the general public." He further emphasized the significance by noting that these reductions are comparable to the benefits observed from major lifestyle interventions, such as quitting smoking, highlighting the profound impact a simple vaccine can have.

Understanding Atherosclerotic Heart Disease and Its Global Burden

Atherosclerotic heart disease remains a leading cause of morbidity and mortality worldwide. In the United States alone, millions live with ASCVD, which includes conditions like coronary artery disease, peripheral artery disease, and cerebrovascular disease. The condition arises from the gradual accumulation of fatty deposits, cholesterol, and other substances (plaque) within the artery walls, leading to hardening and narrowing of the arteries. This restricts blood flow, depriving organs and tissues of essential oxygen and nutrients. Patients with existing ASCVD are inherently at a higher risk for recurrent cardiovascular events, making any intervention that can mitigate this risk immensely valuable. The economic burden of ASCVD is also staggering, encompassing direct medical costs, lost productivity, and long-term care, estimated to be hundreds of billions of dollars annually in the U.S. alone. Therefore, preventive strategies that can reduce the incidence of major cardiovascular events carry significant public health and economic implications.

The Shingles-Cardiovascular Link: A Growing Body of Evidence

The shingles vaccine protects against herpes zoster, a viral infection caused by the reactivation of the varicella-zoster virus (VZV), the same virus responsible for chickenpox. After an initial chickenpox infection, VZV lies dormant in nerve tissues and can reactivate years later, particularly in older adults or those with weakened immune systems. This reactivation manifests as shingles, characterized by a painful, blistering rash that typically affects one side of the body. A common and debilitating complication is post-herpetic neuralgia (PHN), severe nerve pain that can persist for months or even years after the rash has cleared, affecting up to 10-18% of shingles patients. Beyond the immediate discomfort and long-term pain, earlier research has increasingly pointed to a more insidious link between shingles infection and cardiovascular health.

Studies conducted over the past decade have demonstrated that an active shingles infection can trigger systemic inflammation and endothelial dysfunction, leading to an increased risk of blood clot formation. This heightened thrombotic risk, particularly in the brain and heart, has been associated with a transient but significant spike in the incidence of heart attacks, strokes, and venous thromboembolism (VTE) in the weeks and months following a shingles episode. For instance, a meta-analysis published in 2021 found a significantly increased risk of stroke and myocardial infarction (heart attack) following a herpes zoster infection, with the risk peaking in the first few weeks and gradually declining over several months. By preventing the acute inflammatory response and viral replication associated with shingles, the vaccine effectively preempts this cascade of events that can adversely impact the cardiovascular system.

Mechanism of Protection: How the Vaccine May Shield the Heart

The precise mechanisms through which shingles vaccination confers cardiovascular protection are believed to involve several pathways. When VZV reactivates and causes shingles, it can lead to a robust inflammatory response. This inflammation isn’t confined to the skin and nerves; it can become systemic, impacting blood vessels throughout the body. Systemic inflammation is a known risk factor for cardiovascular disease progression, contributing to plaque instability, endothelial dysfunction, and increased coagulability.

The vaccine, by preventing the shingles infection itself, prevents this inflammatory surge. This means the body avoids the acute stress response, the release of pro-inflammatory cytokines, and the activation of clotting pathways that can precipitate cardiovascular events. Furthermore, VZV has been detected in atherosclerotic plaques in some studies, suggesting a potential direct role of the virus in exacerbating plaque instability. While more research is needed to fully elucidate these intricate mechanisms, the prevailing hypothesis is that preventing the viral reactivation and subsequent inflammatory storm is key to reducing cardiovascular complications.

Methodology of the Landmark Study

To conduct this comprehensive study, researchers leveraged TriNetX, a vast federated research network that aggregates de-identified electronic medical records from millions of Americans across numerous healthcare organizations. This extensive database allowed for a robust analysis of real-world clinical data.

The study cohort comprised adults aged 50 years or older who had a documented diagnosis of atherosclerotic disease between 2018 and 2025. This timeframe ensured the inclusion of data predominantly reflecting the use of the newer, highly effective recombinant zoster vaccine (Shingrix), though the older live-attenuated vaccine (Zostavax) was also considered if administered within the study period. The analysis included two well-matched groups: 123,411 individuals who had received at least one dose of a shingles vaccine and an equal number of unvaccinated individuals. Crucially, both groups were carefully matched on a wide array of demographic factors (age, sex, race, ethnicity) and other significant health conditions (e.g., hypertension, diabetes, hyperlipidemia, smoking status, chronic kidney disease, prior heart attack or stroke, use of statins or antiplatelet medications). This rigorous matching process was designed to minimize confounding variables and ensure that any observed differences in outcomes could be more confidently attributed to vaccination status rather than underlying health disparities or socioeconomic factors (such as housing, economic circumstances, social environment, employment, education, and literacy, which were also adjusted for).

Researchers meticulously tracked heart-related outcomes that occurred between one month and one year after the vaccination date (or the equivalent index date for the unvaccinated control group). This specific window was chosen to capture the short-to-medium term effects of vaccination while allowing sufficient time for vaccine efficacy to develop. The primary outcomes of interest included major adverse cardiac events (MACE), encompassing heart attack, stroke, and cardiovascular death, as well as specific events like heart failure and all-cause mortality.

Expert Perspectives and Public Health Implications

The findings from this study reinforce existing public health recommendations and offer a powerful new incentive for vaccination. The Centers for Disease Control and Prevention (CDC) currently recommends two doses of the recombinant zoster vaccine (Shingrix) for adults aged 50 years and older, as well as for younger individuals (19 years and older) who have weakened immune systems. Despite these recommendations, shingles vaccination rates, while improving, still lag behind other adult vaccines. For example, as of 2021, only about one-third of adults aged 60 years or older had received the recommended two doses of the shingles vaccine.

Dr. Nguyen’s comments highlight the broader significance: "Vaccines are one of the most important medicines we have to prevent disease. Sometimes patients are unsure about whether they should get a vaccine or not, particularly in an age of disinformation. These results provide another reason for them to elect to get the vaccine." This sentiment resonates strongly with public health advocates who constantly battle misinformation and vaccine hesitancy. The American College of Cardiology, by featuring such research at its annual scientific session, underscores the growing recognition within the cardiology community of the multifaceted benefits of preventive health measures, including vaccination. This research could catalyze discussions among healthcare providers and patients about integrating shingles vaccination more actively into comprehensive cardiovascular risk management strategies.

Broader Impact and Previous Research

This study is not an isolated finding but builds upon a foundation of increasing evidence. A previous study, anticipated to be published in 2025, further supports the long-term benefits of shingles vaccination. That research, focusing on generally healthy adults, found that shingles vaccination was associated with a 23% reduction in cardiovascular events, with benefits that could last up to eight years. This suggests that the cardioprotective effects are not limited to high-risk individuals and may offer sustained advantages.

The implications for clinical practice are profound. While current guidelines for managing ASCVD primarily focus on cholesterol management, blood pressure control, diabetes management, and lifestyle modifications, these new findings suggest that shingles vaccination could become a more explicitly recommended adjunctive therapy for cardiovascular protection, particularly in older adults or those with existing heart conditions. Integrating this into routine care could significantly reduce the burden of cardiovascular disease. From a public health perspective, these findings provide a compelling argument for increased vaccination efforts, potentially leading to improved population-level cardiovascular health outcomes and substantial healthcare cost savings over time by preventing costly acute cardiac events.

Addressing Study Limitations and Future Directions

While the study offers robust evidence, the researchers acknowledge certain limitations inherent in observational studies using real-world data. One important consideration is the follow-up period, which was limited to one year after vaccination. While this provided crucial short-to-medium term insights, the long-term effects beyond a year may differ, though previous research suggests benefits can persist for much longer.

Another potential limitation, common in observational research, is the "healthy user bias." Individuals who choose to get vaccinated may also be more health-conscious overall, adhering to healthier lifestyles, regularly seeing their doctors, and engaging in other preventive behaviors. While the researchers made extensive adjustments for a wide range of demographic, health, and socioeconomic factors to mitigate this bias, it is still possible that some unmeasured confounding factors could have influenced the observed benefits. However, the study’s massive sample size and sophisticated statistical methods provide strong evidence for a meaningful association between shingles vaccination and reduced heart risk, even after accounting for numerous variables.

Future research will be crucial to further solidify these findings. Longer-term prospective studies with extended follow-up periods would provide valuable data on the durability of the cardioprotective effects. Additionally, research aimed at delving deeper into the precise biological mechanisms by which the shingles vaccine influences cardiovascular health would enhance our understanding and potentially uncover new therapeutic targets. Randomized controlled trials, while challenging for vaccine efficacy studies in general populations, could offer the highest level of evidence, although the clear benefits already observed make such trials ethically complex for denying a proven vaccine to a control group.

In conclusion, this groundbreaking research presented at ACC.26 offers compelling evidence that the shingles vaccine is a powerful tool in preventive cardiology, significantly reducing serious heart-related events and all-cause mortality in patients with existing atherosclerotic heart disease. As Dr. Nguyen affirmed, "These results provide another reason for them to elect to get the vaccine," underscoring the vital role of vaccination in safeguarding public health in an increasingly complex medical landscape.

Dr. Nguyen is scheduled to present the study, titled "Herpes Zoster Vaccination and Risk of Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease," on Monday, March 30, at 12:30 p.m. CT / 17:30 UTC in Posters, Hall E, at the American College of Cardiology’s Annual Scientific Session.